Ascendiant raises Outlook Therapeutics target to $10.50
Ascendiant Capital increased its price target on Outlook Therapeutics (OTLK) to $10.50 from $10.00 following the FDA approval of LYTENAVA.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.